Votrient, generically known as pazopanib, is a medication primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking certain proteins that promote the growth of cancer cells. By inhibiting these proteins, Votrient can slow down the progression of the disease and help control symptoms. It is administered orally in the form of tablets. As with any cancer therapy, it may cause side effects, and its use is typically managed by healthcare professionals experienced in the treatment of cancer. Votrient represents a targeted approach to cancer treatment, focusing on the molecular and cellular changes specific to cancer cells.